5 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 5 of 5 clinical reviews.
Evidence-based review of MOTS-c mitochondrial peptide efficacy differences in Black and African ancestry populations, including pharmacogenomic factors, dosing considerations, and clinical gaps.
A clinician-focused review of how Black and African ancestry genetics affect MOTS-c mitochondrial peptide safety, dosing, and pharmacogenomics, with cited evidence and practical guidance.
East Asian patients may respond to MOTS-c differently due to mitochondrial haplogroup distribution, CYP enzyme polymorphisms, and lower BMI thresholds. This clinical guide reviews the pharmacogenomic evidence and proposed dose considerations.
A clinician-focused review of MOTS-c dosing considerations for Hispanic and Latino patients, covering mitochondrial genetics, insulin-resistance phenotypes, CYP variants, and practical dose-titration guidance.
A clinical review of MOTS-c mitochondrial peptide safety, pharmacogenomics, and dosing considerations specific to Hispanic and Latino patients, including mitochondrial haplogroup data, insulin-resistance phenotypes, and emerging ethnicity-stratified evidence.